Electropharmacology sells SofPulse to ADM:
This article was originally published in Clinica
Electropharmacology has sold the assets in SofPulse, a palliative pain treatment device, to ADM Tronics, a Northvale, New Jersey company making its first entry into the US devices market. The SofPulse divestiture is the first stage in Pompano Beach, Florida-based Electropharmacology's plan to restructure around the Pulsed Electromagnetic Signals (PEMS) technology, aimed at "large markets such as cancer, inflammation and tissue regeneration". ADM plans to expand distribution of SofPulse in the US and to target present distributors of its Sonotron device outside the US. SofPulse last year generated revenues of $1.5 million.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.